Sanofi Ends Amlitelimab Atopic Dermatitis Development, Will Not Seek Global Regulatory Approval
Sanofi has discontinued amlitelimab in moderate-to-severe atopic dermatitis and will not pursue global regulatory submissions, citing ESTUARY phase 3 data that did not show a meaningful edge over standard of care. Full-year 2026 guidance is unaffected.
